RXRX
Recursion Pharmaceuticals Inc - Class A (RXRX)
Healthcare • NASDAQ • $3.32+1.53%
- Symbol
- RXRX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $3.32
- Daily Change
- +1.53%
- Market Cap
- $1.76B
- Trailing P/E
- N/A
- Forward P/E
- -3.75
- 52W High
- $7.18
- 52W Low
- $2.80
- Analyst Target
- $6.57
- Dividend Yield
- N/A
- Beta
- 1.05
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1…
Company websiteResearch RXRX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.